Tetracycline delays ocular motility decline in chronic progressive external ophthalmoplegia

Omar, Ayman; Johnson, Lenworth N.

doi:10.1212/01.wnl.0000258659.21421.b0

Cited by 6 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 Other potential approaches include neuroprotective strategies; for example, tetracycline seemed to delay ocular motility decline in one isolated PEO case. 73 Moreover, the role of mitochondrial dysfunction and oxidative stress in the pathogenesis of neurodegenerative diseases is well documented. 4 It will be important to develop a better understanding of the role of oxidative stress and mitochondrial energy metabolism in neurodegeneration, since this may lead to the development of more effective treatment strategies for these devastating disorders.…”

Section: Resultsmentioning

confidence: 99%

Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction

Orsucci

Filosto²,

Siciliano

et al. 2009

Nutrition Reviews

View full text Add to dashboard Cite

Mitochondrial disorders (MDs) are caused by impairment of the mitochondrial electron transport chain (ETC). The ETC is needed for oxidative phosphorylation, which provides the cell with the most efficient energy outcome in terms of ATP production. One of the pathogenic mechanisms of MDs is the accumulation of reactive oxygen species. Mitochondrial dysfunction and oxidative stress appear to also have a strong impact on the pathogenesis of neurodegenerative diseases and cancer. The treatment of MDs is still inadequate. Therapies that have been attempted include ETC cofactors, other metabolites secondarily decreased in MDs, antioxidants, and agents acting on lactic acidosis. However, the role of these dietary supplements in the treatment of the majority of MDs remains unclear. This article reviews the rationale for their use and their role in clinical practice in the context of MDs and other disorders involving mitochondrial dysfunction.

show abstract

Section: Resultsmentioning

confidence: 99%

Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction

Orsucci

Filosto²,

Siciliano

et al. 2009

Nutrition Reviews

View full text Add to dashboard Cite

show abstract

“…Moreover, it has been reported an improvement in ocular motility in a patient with ocular mitochondrial myopathy (progressive external ophthalmoplegia) following treatment with tetracycline [39]. For this reason, our group performed a double-blind randomized pilot study (followed by an adjunctive open-label phase) in order to evaluate if tetracycline (500 mg/day x 14 days/month x 3 months) could be useful in patients (n = 16) with progressive external ophthalmoplegia [40].…”

Section: Mitochondrial Disordersmentioning

confidence: 99%

Tetracyclines and Neuromuscular Disorders

Orsucci

Mancuso²,

Filosto³

et al. 2012

View full text Add to dashboard Cite

Tetracyclines are a class of antibiotics which could act as neuroprotective molecules in several neurological disorders, such as Huntington disease, Parkinson disease, stroke and multiple sclerosis. The main biological effects of tetracyclines are the inhibition of microglial activation, the attenuation of apoptosis and the suppression of reactive oxygen species production. The anti-apoptotic effect of tetracyclines involves the mitochondrion, and the major target for neuroprotective effects of tetracyclines lies within the complex network that links mitochondria, oxidative stress and apoptosis.Neuromuscular disorders are due to dysfunction of motor neurons, peripheral nerves, neuromuscular junction, or skeletal muscle itself. Animal studies have shown that minocycline could play neuroprotective effects in amyotrophic lateral sclerosis, but these positive findings have not been replicated in patients. Other neuromuscular disorders which tetracyclines may benefit are Guillain-Barré syndrome and other neuropathies, muscular dystrophies and mitochondrial disorders. However, well-designed double-blind controlled trials are still needed. Further studies are strongly needed to establish the most appropriate timing and dosage, as well as the indications for which tetracyclines could be effective and safe.Here, we review the neuroprotective effects of tetracyclines in animal models, the clinical studies in humans, and we focus on their potential application in patients with neuromuscular disorders.

show abstract

“…In an isolated case of Chronic Progressive External Ophthalmoplegia (cPEO) tetracycline seemed to delay ocular motility decline [60].…”

Section: ) Other Cofactors and Optionsmentioning

confidence: 99%

Current Options in the Treatment of Mitochondrial Diseases

Scarpelli¹,

Cotelli²,

Mancuso³

et al. 2010

RPCN

View full text Add to dashboard Cite

Mitochondrial diseases (MD) are disorders caused by an impairment of the mitochondrial respiratory chain function. They are usually progressive, isolated or multi-system diseases and have variable times of onset. Because mitochondria have their own DNA (mtDNA), MD can be caused by mutations in both mtDNA and nuclear DNA (nDNA). The complexity of genetic control of mitochondrial function is in part responsible for the intra- and inter-familiar clinical heterogeneity of this class of diseases. Despite the remarkable progress in understanding of the molecular bases of these disorders, therapy of MD is quite inadequate. Present options of treatment mainly include physical, pharmacological and gene therapy approaches. Aerobic exercise and physical therapy is useful to prevent or correct deconditioning and may improve exercise tolerance. Pharmacological approach is based on removing noxious metabolites, using reactive oxygen species scavengers and administrating vitamins and cofactors which is especially important in case of primary deficiencies of specific compounds such as Coenzyme Q10. Gene therapy is fascinating but it is difficult to apply because of polyplasmy and heteroplasmy. Experimental methods include gene shifting, allotopic expression, mitochondrial transfection or correcting mtDNA mutations with specific restriction endonucleases. Here, we discussed some recent patents. Progresses in each of these fields may open interesting perspectives for the future.

show abstract

Tetracycline delays ocular motility decline in chronic progressive external ophthalmoplegia

Cited by 6 publications

References 8 publications

Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction

Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction

Tetracyclines and Neuromuscular Disorders

Current Options in the Treatment of Mitochondrial Diseases

Contact Info

Product

Resources

About